Abstract |
Antiretroviral drug resistance is one of the complications of highly active antiretroviral therapy ( HAART). Second-generation non- nucleoside reverse transcriptase inhibitors (NNRTIs) are being developed for use in patients infected with HIV-1 because of the enhanced activity of these inhibitors against viruses that are resistant to the first-generation NNRTIs. IDX-899 (GSK-2248761), under development by Idenix Pharmaceuticals Inc and ViiV Healthcare, is an aryl phosphinate- indole second-generation NNRTI that potently and selectively inhibits wild-type and NNRTI-resistant HIV-1 in vitro. Preclinical data for IDX-899 suggest a significantly greater barrier to resistance compared with that of the first-generation NNRTI efavirenz. Two pathways of resistance have been identified for IDX-899 in vitro that include Glu138Lys and Val90Ile/Tyr181Cys mutations. Pharmacokinetic studies demonstrated that IDX-899 exhibits linear, dose-proportional and food-dependent pharmacokinetics; Cmin concentrations achieved with this drug allow once-daily dosing. In phase I clinical trials, IDX-899 reduced HIV-1 RNA and increased CD4+ cell counts in treatment-naïve patients infected with HIV-1. At the time of publication, a phase II clinical trial of IDX-899 was being conducted.
|
Authors | Olga M Klibanov, Roberta L Kaczor |
Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 11
Issue 2
Pg. 237-45
(Feb 2010)
ISSN: 2040-3429 [Electronic] England |
PMID | 20112173
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-HIV Agents
- IDX 899
- Indoles
- Phosphinic Acids
- Reverse Transcriptase Inhibitors
|
Topics |
- Animals
- Anti-HIV Agents
(pharmacokinetics, pharmacology, therapeutic use)
- Antiretroviral Therapy, Highly Active
(adverse effects, methods)
- Clinical Trials as Topic
- Drug Evaluation, Preclinical
- Drug Resistance, Viral
- HIV Infections
(drug therapy, virology)
- HIV-1
(drug effects)
- Humans
- Indoles
(pharmacokinetics, pharmacology, therapeutic use)
- Phosphinic Acids
(pharmacokinetics, pharmacology, therapeutic use)
- Reverse Transcriptase Inhibitors
(pharmacokinetics, pharmacology, therapeutic use)
|